[
  {
    "variant_string_id": "EGFR L858R",
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The paper describes EGFR mutations, including L858R, as drivers of non-small cell lung cancer (NSCLC) that confer dependency on ATP binding and downstream signaling.",
        "judgment": "Yes",
        "reasoning": "The paper explicitly links EGFR mutations like L858R to NSCLC and explains their function in ATP binding and signaling.",
        "next_step_or_outcome": "Proceed to Step 2"
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "The assay uses an enzyme activity assay, which directly measures the ATP-binding capability of the mutated EGFR protein and its effect on downstream signaling.",
        "judgment": "Yes",
        "reasoning": "Measuring ATP binding and signaling is a direct assessment of the functional impact of EGFR mutations and aligns with the described disease mechanism.",
        "next_step_or_outcome": "Proceed to Step 1a"
      },
      {
        "step_name": "Step 1a: Basic Controls and Replicates",
        "extracted_paper_info": "The enzyme activity assays include a wild-type EGFR control and a null mutant as a negative control. The experiments were repeated three times (n=3).",
        "judgment": "Yes",
        "reasoning": "Both necessary controls (wild-type and null mutant) were used, and multiple replicates (n=3) were performed.",
        "next_step_or_outcome": "Proceed to Step 4"
      },
      {
        "step_name": "Step 1b: Variant Controls",
        "extracted_paper_info": "The paper details a comparison between the L858R mutant and a series of other EGFR variants categorized as known pathogenic and benign. These variants were run in the same enzyme activity assays as L858R.",
        "judgment": "Yes",
        "reasoning": "The study used variant controls in the assay to compare L858R performance against known pathogenic and benign variants, fulfilling the condition to proceed directly to the step 4.",
        "next_step_or_outcome": "Proceed to Step 4"
      },
      {
        "step_name": "Step 4: Apply evidence to individual variant interpretation",
        "extracted_paper_info": "The study used statistical analyses to evaluate the effect of EGFR mutation to the ATP binding site, generating an OddsPath value of 21.6 for the L858R variant.",
        "judgment": "Yes",
        "reasoning": "The study generated a robust OddsPath value.",
        "next_step_or_outcome": "Determine the PS3/BS3 classification"
      }
    ],
    "final_evidence_strength": {
      "type": "Pathogenic",
      "strength": "PS3_very_strong"
    },
    "overall_conclusion": "Given the clear link between EGFR mutations and NSCLC, the direct assessment of ATP binding capability using a validated enzyme activity assay, inclusion of wild-type, null mutant and a series of known pathogenic and benign variants, and a very high OddsPath value (21.6), this variant is assigned a PS3_very_strong classification."
  }
]